{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:08:14Z","timestamp":1781222894390,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005375","name":"Latvian Council of Science","doi-asserted-by":"crossref","award":["Izp-2022\/1-0080"],"award-info":[{"award-number":["Izp-2022\/1-0080"]}],"id":[{"id":"10.13039\/501100005375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43535-3","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T15:44:57Z","timestamp":1776527097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antigen-specific B cell responses in treatment-naive and chlorambucil-treated patients with chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"16","author":[{"given":"Baiba","family":"\u0160lisere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberts","family":"K\u0101rkli\u0146\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiga","family":"Pl\u0113germane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva E.","family":"Morozova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Petrovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dace","family":"Pjanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lejniece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u012bne","family":"O\u013cei\u0146ika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"43535_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"M Hallek","year":"2025","unstructured":"Hallek, M. Chronic lymphocytic leukemia: 2025 Update on the epidemiology, pathogenesis, diagnosis, and therapy. Am. J. Hematol. 100, 450\u2013480. https:\/\/doi.org\/10.1002\/ajh.27546 (2025).","journal-title":"Am. J. Hematol."},{"key":"43535_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cyto.b.21595","volume":"94","author":"AC Rawstron","year":"2018","unstructured":"Rawstron, A. C. et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project. Cytometry B Clin. Cytom. 94, 121\u2013128. https:\/\/doi.org\/10.1002\/cyto.b.21595 (2018).","journal-title":"Cytometry B Clin. Cytom."},{"key":"43535_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738915","volume":"12","author":"A Allegra","year":"2021","unstructured":"Allegra, A., Tonacci, A., Musolino, C., Pioggia, G. & Gangemi, S. Secondary immunodeficiency in hematological malignancies: Focus on multiple myeloma and chronic lymphocytic leukemia. Front. Immunol. 12, 738915. https:\/\/doi.org\/10.3389\/fimmu.2021.738915 (2021).","journal-title":"Front. Immunol."},{"key":"43535_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","volume":"126","author":"F Forconi","year":"2015","unstructured":"Forconi, F. & Moss, P. Perturbation of the normal immune system in patients with CLL. Blood 126, 573\u2013581. https:\/\/doi.org\/10.1182\/blood-2015-03-567388 (2015).","journal-title":"Blood"},{"key":"43535_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/10428194.2012.706285","volume":"54","author":"JA Freeman","year":"2013","unstructured":"Freeman, J. A. et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk. Lymphoma 54, 99\u2013104. https:\/\/doi.org\/10.3109\/10428194.2012.706285 (2013).","journal-title":"Leuk. Lymphoma"},{"key":"43535_CR6","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1002\/cncr.29438","volume":"121","author":"SA Parikh","year":"2015","unstructured":"Parikh, S. A. et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer 121, 2883\u20132891. https:\/\/doi.org\/10.1002\/cncr.29438 (2015).","journal-title":"Cancer"},{"key":"43535_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jha2.95","volume":"1","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. EJHaem 1, 537\u2013544. https:\/\/doi.org\/10.1002\/jha2.95 (2020).","journal-title":"EJHaem"},{"key":"43535_CR8","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1038\/s41375-018-0164-3","volume":"32","author":"I Criado","year":"2018","unstructured":"Criado, I. et al. Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. Leukemia 32, 2701\u20132705. https:\/\/doi.org\/10.1038\/s41375-018-0164-3 (2018).","journal-title":"Leukemia"},{"key":"43535_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1020740","volume":"12","author":"T Andrieu","year":"2022","unstructured":"Andrieu, T. et al. Mass cytometry analysis reveals attrition of naive and anergized self-reactive non-malignant B cells in chronic lymphocytic leukemia patients. Front. Oncol. 12, 1020740. https:\/\/doi.org\/10.3389\/fonc.2022.1020740 (2022).","journal-title":"Front. Oncol."},{"key":"43535_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114966","volume":"9","author":"M Pasiarski","year":"2014","unstructured":"Pasiarski, M. et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients\u2014Preliminary report. PLoS ONE 9, e114966. https:\/\/doi.org\/10.1371\/journal.pone.0114966 (2014).","journal-title":"PLoS ONE"},{"key":"43535_CR11","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/s0264-410x(00)00409-6","volume":"19","author":"A Hartkamp","year":"2001","unstructured":"Hartkamp, A., Mulder, A. H., Rijkers, G. T., van Velzen-Blad, H. & Biesma, D. H. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine 19, 1671\u20131677. https:\/\/doi.org\/10.1016\/s0264-410x(00)00409-6 (2001).","journal-title":"Vaccine"},{"key":"43535_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood.2020008758","volume":"137","author":"C Pleyer","year":"2021","unstructured":"Pleyer, C. et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood 137, 185\u2013189. https:\/\/doi.org\/10.1182\/blood.2020008758 (2021).","journal-title":"Blood"},{"key":"43535_CR13","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","volume":"34","author":"L Scarfo","year":"2020","unstructured":"Scarfo, L. et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 34, 2354\u20132363. https:\/\/doi.org\/10.1038\/s41375-020-0959-x (2020).","journal-title":"Leukemia"},{"key":"43535_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00177-z","volume":"9","author":"JL Pinana","year":"2020","unstructured":"Pinana, J. L. et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp. Hematol. Oncol. 9, 21. https:\/\/doi.org\/10.1186\/s40164-020-00177-z (2020).","journal-title":"Exp. Hematol. Oncol."},{"key":"43535_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3324\/haematol.2021.279196","volume":"107","author":"O Benjamini","year":"2022","unstructured":"Benjamini, O. et al. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica 107, 625\u2013634. https:\/\/doi.org\/10.3324\/haematol.2021.279196 (2022).","journal-title":"Haematologica"},{"key":"43535_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/ejh.13722","volume":"108","author":"M Morawska","year":"2022","unstructured":"Morawska, M. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia. Eur. J. Haematol. 108, 91\u201398. https:\/\/doi.org\/10.1111\/ejh.13722 (2022).","journal-title":"Eur. J. Haematol."},{"key":"43535_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejca.2021.06.008","volume":"154","author":"J Barriere","year":"2021","unstructured":"Barriere, J., Re, D., Peyrade, F. & Carles, M. Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer. Eur. J. Cancer 154, 66\u201372. https:\/\/doi.org\/10.1016\/j.ejca.2021.06.008 (2021).","journal-title":"Eur. J. Cancer"},{"key":"43535_CR18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ajh.26284","volume":"96","author":"K Herzog Tzarfati","year":"2021","unstructured":"Herzog Tzarfati, K. et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am. J. Hematol. 96, 1195\u20131203. https:\/\/doi.org\/10.1002\/ajh.26284 (2021).","journal-title":"Am. J. Hematol."},{"key":"43535_CR19","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","volume":"35","author":"LE Roeker","year":"2021","unstructured":"Roeker, L. E. et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia 35, 2703\u20132705. https:\/\/doi.org\/10.1038\/s41375-021-01270-w (2021).","journal-title":"Leukemia"},{"key":"43535_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004157","volume":"20","author":"K Qin","year":"2023","unstructured":"Qin, K. et al. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study. PLoS Med. 20, e1004157. https:\/\/doi.org\/10.1371\/journal.pmed.1004157 (2023).","journal-title":"PLoS Med."},{"key":"43535_CR21","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu, Y. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 137, 3165\u20133173. https:\/\/doi.org\/10.1182\/blood.2021011568 (2021).","journal-title":"Blood"},{"key":"43535_CR22","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3324\/haematol.2016.159012","volume":"102","author":"I Criado","year":"2017","unstructured":"Criado, I. et al. Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: Implications for disease progression. Haematologica 102, 1238\u20131246. https:\/\/doi.org\/10.3324\/haematol.2016.159012 (2017).","journal-title":"Haematologica"},{"key":"43535_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078925","volume":"8","author":"K Vanura","year":"2013","unstructured":"Vanura, K. et al. Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia. PLoS ONE 8, e78925. https:\/\/doi.org\/10.1371\/journal.pone.0078925 (2013).","journal-title":"PLoS ONE"},{"key":"43535_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02458","volume":"10","author":"I Sanz","year":"2019","unstructured":"Sanz, I. et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front. Immunol. 10, 2458. https:\/\/doi.org\/10.3389\/fimmu.2019.02458 (2019).","journal-title":"Front. Immunol."},{"key":"43535_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.imlet.2023.03.003","volume":"255","author":"L Beckers","year":"2023","unstructured":"Beckers, L., Somers, V. & Fraussen, J. IgD(-)CD27(-) double negative (DN) B cells: Origins and functions in health and disease. Immunol. Lett. 255, 67\u201376. https:\/\/doi.org\/10.1016\/j.imlet.2023.03.003 (2023).","journal-title":"Immunol. Lett."},{"key":"43535_CR26","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1038\/s41467-021-23074-3","volume":"12","author":"G Song","year":"2021","unstructured":"Song, G. et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat. Commun. 12, 2938. https:\/\/doi.org\/10.1038\/s41467-021-23074-3 (2021).","journal-title":"Nat. Commun."},{"key":"43535_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.103951","volume":"25","author":"MS Ercanoglu","year":"2022","unstructured":"Ercanoglu, M. S. et al. No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults. iScience 25, 103951. https:\/\/doi.org\/10.1016\/j.isci.2022.103951 (2022).","journal-title":"iScience"},{"key":"43535_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.chom.2021.12.005","volume":"30","author":"CY Lin","year":"2022","unstructured":"Lin, C. Y. et al. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell Host Microbe 30, 83-96 e84. https:\/\/doi.org\/10.1016\/j.chom.2021.12.005 (2022).","journal-title":"Cell Host Microbe"},{"key":"43535_CR29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ajh.27218","volume":"99","author":"A Campanella","year":"2024","unstructured":"Campanella, A. et al. Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL. Am. J. Hematol. 99, 745\u2013750. https:\/\/doi.org\/10.1002\/ajh.27218 (2024).","journal-title":"Am. J. Hematol."},{"key":"43535_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/bjh.18962","volume":"202","author":"CL Pinder","year":"2023","unstructured":"Pinder, C. L. et al. Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination. Br. J. Haematol. 202, 1091\u20131103. https:\/\/doi.org\/10.1111\/bjh.18962 (2023).","journal-title":"Br. J. Haematol."},{"key":"43535_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14090890","author":"B Slisere","year":"2025","unstructured":"Slisere, B., Karklins, R., Rivkina, A., Lejniece, S. & Oleinika, K. Attenuated SARS-CoV-2-specific T cell responses are associated with T follicular helper cell expansion in treatment-naive chronic lymphocytic leukemia patients. Pathogens https:\/\/doi.org\/10.3390\/pathogens14090890 (2025).","journal-title":"Pathogens"},{"key":"43535_CR32","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek, M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131, 2745\u20132760. https:\/\/doi.org\/10.1182\/blood-2017-09-806398 (2018).","journal-title":"Blood"},{"key":"43535_CR33","unstructured":"Swerdlow, S. H., World Health, O. & International Agency for Research on, C. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised fourth edition. edn, (International Agency for Research on Cancer, 2017)."},{"key":"43535_CR34","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","volume":"28","author":"FA Bonilla","year":"2008","unstructured":"Bonilla, F. A. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol. Allergy Clin. N. Am. 28, 803\u2013819, ix. https:\/\/doi.org\/10.1016\/j.iac.2008.06.006 (2008).","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"43535_CR35","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu, T. & Vilo, J. ClustVis: A web tool for visualizing clustering of multivariate data using Principal component analysis and heatmap. Nucleic Acids Res. 43, W566-570. https:\/\/doi.org\/10.1093\/nar\/gkv468 (2015).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43535-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43535-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43535-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:51:07Z","timestamp":1781221867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43535-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43535"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43535-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18292"}}